AXCELIS TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AXCELIS TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $839.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.13B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $920.00M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $662.43M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $474.56M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $107.72M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $69.45M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $74.31M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $91.48M | Mar 2, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $839.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.02B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.13B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $920.00M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $662.43M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $474.56M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $342.96M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $442.58M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $410.56M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $266.98M | Mar 11, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $116.40M | Mar 14, 2018 |
| FY2017 | Sep 30, 2017 | $104.48M | Mar 14, 2018 |
| FY2017 | Jun 30, 2017 | $102.79M | Mar 14, 2018 |
| FY2017 | Mar 31, 2017 | $86.89M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $69.36M | Mar 14, 2018 |
| FY2017 | Sep 30, 2016 | $65.65M | Mar 14, 2018 |
| FY2017 | Jun 30, 2016 | $64.45M | Mar 14, 2018 |
| FY2017 | Mar 31, 2016 | $67.52M | Mar 14, 2018 |
| FY2016 | Dec 31, 2015 | $70.46M | Mar 14, 2017 |
| FY2016 | Sep 30, 2015 | $79.32M | Mar 14, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $376.85M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $454.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $491.30M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $401.79M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $286.45M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $198.58M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $44.32M | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | $30.58M | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | $31.75M | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | $37.51M | Mar 2, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.24M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $200.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $246.26M | Feb 26, 2026 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.32M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $210.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $265.80M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $212.36M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $127.33M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $58.04M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $24.21M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $59.96M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $47.84M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $16.62M | Mar 11, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.96M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $105.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $96.91M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $78.36M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $65.43M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $61.83M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $53.93M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $51.88M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $43.07M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $34.40M | Mar 11, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.31M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $140.82M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $156.87M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $215.61M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $150.19M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $69.70M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | ($13.59M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $46.97M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $56.28M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($8.79M) | Mar 11, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $20.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $10.68M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $8.72M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $7.43M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $11.97M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $4.72M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $7.29M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $2.51M | Mar 11, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.35B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.28B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.01B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $753.24M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $624.62M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $548.09M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $548.44M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $488.22M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $302.23M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $326.67M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $335.99M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $417.09M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $346.39M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $214.28M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $143.02M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $128.67M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $140.10M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $134.61M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $100.78M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $864.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $667.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $538.96M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $481.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $419.43M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $408.34M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $353.61M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $201.46M | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $503.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $470.32M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $319.51M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $118.89M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($22.72M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | ($91.97M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($140.23M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($157.26M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($204.75M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($331.70M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.45M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $123.51M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $167.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $185.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $294.92M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $203.48M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $139.88M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $177.99M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $133.41M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $70.79M | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 6 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 2, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30.72M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 32.37M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 32.69M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 32.78M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 33.24M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 33.63M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 32.59M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 32.56M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 32.05M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | 29.52M | Mar 14, 2018 |